Corindus, a Siemens Healthineers Company that develops precision vascular robotics, has launched a new set of automated robotic movements in the technIQ Series for its CorPath GRX System.
The new features are designed to replicate manual techniques of highly skilled interventionalists and are expected to reduce procedure time and make complex coronary and peripheral procedures more predictable.
“This new software algorithm gives the operator new possibilities to advance and facilitate treatment, especially with complex lesions,” said Dr. Jean Fajadet, the co-director of interventional cardiology at Clinique Pasteur in Toulouse, France, in a statement.
Fajadet was the first to use the automated movements for in-human coronary procedures. Their use reduced procedure time association with wire and device manipulation.
CorPath is designed to robotically perform percutaneous coronary intervention and protect clinicians from radiation exposure in the cath lab, according to Corindus. The automated features are four robotic movements that aid with complex tasks such as crossing lesions, navigating tortuosity and measuring the anatomy for appropriate device size selection.
The software automation is FDA cleared. Corindus also received FDA clearance and CE Mark in 2018 for Rotate on Retract (RoR), the first automated robotic movement in the technIQ Series Procedural Automation, which is a set of automated robotic movements for the CorPath GRX System. It gained FDA clearance
in 2016 for the CorPath GRX System, which is the second generation of its CorPath Vascular Robotics System.
“Automating more movements used in cardiovascular intervention will allow physicians to focus their attention on overall case strategy while equipping them with advanced techniques for navigating the vasculature,” said Wayne Markowitz, executive vice president and head of Corindus, in a statement.